Seminars in Hematology
Volume 43, Issue 4 , Pages 230-239 , October 2006

Drug Resistance in Diffuse Large B-Cell Lymphoma

  • Wyndham H. Wilson

      Affiliations

    • Corresponding Author InformationAddress correspondence to Wyndham H. Wilson, MD, PhD, Center for Cancer Treatment, National Cancer Institute, Bldg 10, Room 4N115, 9000 Rockville Pike, Bethesda, MD 20892.

References 

  1. Wilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis J, et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol. 1995;13:1995–2004
  2. Gaynor ER, Unger JM, Miller TP, Grogan TM, White LA, Mills GM, et al. Infusional CHOP chemotherapy (CVAD) with or without chemosensitizers offers no advantage over standard CHOP therapy in the treatment of lymphoma: A Southwest Oncology Group study. J Clin Oncol. 2001;19:750–755
  3. Lee WP, Lee CL, Lin HC. Glutathione S-transferase and glutathione peroxidase are essential in the early stage of Adriamycin resistance before P-glycoprotein overexpression in HOB1 lymphoma cells. Cancer Chemother Pharmacol. 1996;38:45–51
  4. Alenzi FQ, Wyse RK, Altamimi WG. Apoptosis as a tool for therapeutic agents in haematological diseases. Expert Opin Biol Ther. 2004;4:407–420
  5. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 1993;362:847–849
  6. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727–1733
  7. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 1993;329:1318–1327
  8. Longo DL, DeVita VT, Duffey PL, Wesley MN, Ihde DC, Hubbard S, et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J Clin Oncol. 1991;9:25–38
  9. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med. 1993;328:1002–1006
  10. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A. 1987;84:265–269
  11. Lai GM, Chen YN, Mickley LA, Fojo AT, Bates SE. P-glycoprotein expression and schedule dependence of Adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer. 1991;49:696–703
  12. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. Biochem Pharmacol. 1999;57:727–741
  13. Lynch A, Harvey J, Aylott M, Nicholas E, Burman M, Siddiqui A, et al. Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity. Mutagenesis. 2003;18:345–353
  14. Cole DE, Balis FM, Lowe ES, et al. Pharmacokinetics (pk) and tolerance of doxorubicin (dox) and etoposide (etop) during treatment of aggressive B-cell lymphomas indicate doses need not be routinely reduced for hepatic dysfunction. Proc Am Soc Clin Oncol. 2005;24:(abstr)
  15. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: Results of a tree-structured survival analysis. J Clin Oncol. 1990;8:963–977
  16. Meyer RM, Quirt IC, Skillings JR, Cripps MC, Bramwell VH, Weinerman BH, et al. Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:1770–1776
  17. Kaiser U, Uebelacker I, Abel U, Birkmen J, Trumper L, Schmalenberg H, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for “aggressive” lymphoma. J Clin Oncol. 2002;20:4413–4419
  18. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol—A groupe d’Etude des lymphomes de l’Adulte study. J Clin Oncol. 2000;18:3025–3030
  19. Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: A pharmacodynamic approach with high efficacy. Blood. 2002;99:2685–2693
  20. Lowe E, Balis FM, Cole DE, Goodspeed W, Drbohlav N, Wilson WH. Pharmacokinetics of doxorubicin and doxorubicinol in dose-adjusted EPOCH infusional chemotherapy. Am Assoc Cancer Res. 2002;
  21. Skipper HE, Schabel FM, Wilcox WS. Experimental evaluation of potential anticancer agents (Xiii. On the criteria and kinetics associated with “curability” of experimental leukemia). Cancer Chemother Rep. 1964;35:1–111
  22. Dave SS, Fu K, Wright G, Lam L, Grenier TC, Weisenberger DD, et al. Gene expression distinguishes Burkitt lymphoma from other aggressive lymphomas and identifies patients who are highly curable with intensive chemotherapeutic regimens. ASH Annual Meeting Abstracts. 2000;106:415
  23. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937–1947
  24. Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin’s lymphomas: A prospective Southwest Oncology Group trial. Blood. 1994;83:1460–1466
  25. Pfreundschuh M, Trümper L, Kloess M, et al. 2-weekly vs. 3-weekly CHOP with and without etoposide in for patients >60 years of age with aggressive non-Hodgkin’s lymphoma (NHL): Results of the completed NHL-B-2 trial of the DSHNHL. Blood. 2002;99:(abstr 3060)
  26. Pfreundschuh M, Trümper L, Schmits R, et al. 2-weekly vs. 3-weekly CHOP with and without etoposide in young patients with low-risk (low LDH) aggressive non-Hodgkin’s lymphoma: Results of the completed NHL-B-1 trial of the DSHNHL. Blood. 2002;99:(abstr 340)
  27. Wilson WH, Porcu P, Hurd D, et al. Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103. Proc Am Soc Clin Oncol. 2005;24:(abstr)
  28. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, et al. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin’s lymphomas. Blood. 1997;89:601–609
  29. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med. 1997;337:529–534
  30. Hans CP, Weisenburger DD, Greiner TC, Chan WC, Aoun P, Cochran G, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol. 2005;18:1377–1384
  31. Filipits M, Jaeger U, Pohl G, Stranzl T, Simonitsch I, Kaider A, et al. Cyclin D3 is a predictive and prognostic factor in diffuse large B-cell lymphoma. Clin Cancer Res. 2002;8:729–733
  32. Paik JH, Jeon YK, Park SS, Kim YA, Kim JE, Huh J, et al. Expression and prognostic implications of cell cycle regulatory molecules, p16, p21, p27, p14 and p53 in germinal centre and non-germinal centre B-like diffuse large B-cell lymphomas. Histopathology. 2005;47:281–291
  33. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24:1770–1783
  34. O’Connor OA. Developing new drugs for the treatment of lymphoma. Eur J Haematol. 2005;(suppl):150–158
  35. Sachs L, Lotem J. Control of programmed cell death in normal and leukemic cells: New implications for therapy. Blood. 1993;82:15–21
  36. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990;348:334–336
  37. Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, et al. Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood. 1997;90:244–251
  38. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005;435:677–681
  39. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C, et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2–associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood. 2003;101:4279–4284
  40. Wilson W, Pittaluga S, O’Connor P, Hegde U, Drbohlav N, Janik J, et al. Rituximab may overcome BCL-2-associated chemotherapy resistance in untreated diffuse large B-cell lymphomas. Proc Am Soc Hematol. 2001;99:
  41. Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: A prospective correlative study. Blood. 2006;2005-2010:
  42. Dunleavy K, Pittaluga S, Janik J, Grant N, Steinberg S, Staudt L, et al. Primary mediastinal large B-cell lymphoma (PMBL) outcome is significantly improved by the addition of rituximab to dose adjusted (DA)-EPOCH and overcomes the need for radiation. ASH Annual Meeting Abstracts. 2005;106:623;(abstr)
  43. Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne RD, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003;198:851–862
  44. Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin’s lymphoma B-cell lines: Role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res. 2005;65:264–276
  45. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194:1861–1874
  46. Dunleavy K, Janik J, Gea-Banacloche J, Shovlin M, White T, Goldschmidt N, et al. Phase I/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma. ASH Annual Meeting Abstracts. 2004;104:1385;(abstr)
  47. Wilson WH, Sorbara L, Figg WD, Mont EK, Sausville E, Warren KE, et al. Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: Presentation of a novel therapeutic paradigm. Clin Cancer Res. 2000;6:415–421
  48. Georgakis GV, Younes A. Heat-shock protein 90 inhibitors in cancer therapy: 17AAG and beyond. Future Oncol. 2005;1:273–281
  49. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–994
  50. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511
  51. Dalla-Favera R, Migliazza A, Chang CC, Niu H, Pasqualucci L, Butler M, et al. Molecular pathogenesis of B cell malignancy: The role of BCL-6. Curr Top Microbiol Immunol. 1999;246:257–263
  52. Mittrucker HW, Matsuyama T, Grossman A, Kundig TM, Potter J, Shahinian A, et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science. 1997;275:540–543
  53. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8:68–74
  54. Leitges M, Schmedt C, Guinamard R, Davoust J, Schaal S, Stabel S, et al. Immunodeficiency in protein kinase cbeta-deficient mice. Science. 1996;273:788–791
  55. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, de Leval L, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin’s lymphoma. Blood. 2003;2003-2006:
  56. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2:1281–1288
  57. Wilson WH, et al. Dose-adjusted EPOCH-rituximab in untreated diffuse large B-cell lymphoma: Benefit of rituximab appears restricted to tumors harboring anti-apoptotic mechanisms. ASH Annual Meeting Abstracts. 2003;103:356;(abstr)

PII: S0037-1963(06)00153-3

doi: 10.1053/j.seminhematol.2006.07.005

Seminars in Hematology
Volume 43, Issue 4 , Pages 230-239 , October 2006

Article Tools

* Image Usage & Resolution